Connect with us


Ocugen Plans $53M Public Offering

The company seeks to commercialize gene therapies to cure blindness diseases.




MALVERN, PA — Ocugen Inc. announced the pricing of its underwritten public offering of nearly 16 million shares of common stock.

Gross proceeds are expected to be about $53.5 million before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Ocugen (Nasdaq: OCGN). The offering is expected to close on or about Feb. 25, subject to customary closing conditions.

In addition, Ocugen has granted to the underwriter a 30-day option to purchase up to about 2.4 million additional shares of its common stock.

Ocugen intends to use the net proceeds from the offering for “general corporate purposes, capital expenditures, working capital and general and administrative expenses,” according to a press release.

Ocugen is focused on “discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19.”

According to the company: “Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – ‘one to many’ and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.”



Turn Patients Into Loyal Eyewear Shoppers

80% of patients are browsing eyewear online, are you influencing patients online before your competition? Join thousands of practices thriving with Optify, voted the #1 optical sales tool by EyeVote. Empower your opticians to save time, increase optical revenue, and maximize your EHR data and website with a seamless optical plug-in that keeps patients buying from YOU! Now through August 31st receive a $25 UberEats® gift card when you complete a 15 min demo. Book your demo here..

Promoted Headlines





Get the most important news and business ideas for eyecare professionals every weekday from INVISION.



Most Popular

Link partner: indobet autowin88 vegasslot77 mantra88 ligasedayu warungtoto login sbobet vegas4d indobet ingatbola88 ligaplay dewagg hoki368 qqnusa ligagg zeus138 bro138 bos88 ligaciputra